Hims & Hers Health: Strong Quarterly Numbers, but GLP-1 Withdrawal Weighs on Stock
Reading Time: 4 minutes
After the release of the results for the 4th quarter and the entire year of 2024, shares of Hims & Hers Health Inc. fell by up to 20% in after-hours trading. Although the company presented impressive financial figures, the announcement to cease the sale of commercial GLP-1 drugs containing the active ingredient semaglutide caused uncertainty in the markets. Financial Figures at a Glance The 4th quarter of 2024 was exceptionally successful for Hims & Hers. Revenue increased by 95% compared to the previous year to $481 million, slightly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
